NCT03185793View on ClinicalTrials.gov

Dose-finding and Safety Study of SHR4640 in Subjects With Hyperuricemia

PHASE2CompletedINTERVENTIONAL
Enrollment

198

Participants

Timeline

Start Date

July 20, 2017

Primary Completion Date

July 20, 2018

Study Completion Date

July 20, 2018

Conditions
Hyperuricemia
Interventions
DRUG

Placebo

Placebo once daily for 5 weeks

DRUG

SHR4640

1mg SHR4640 once daily for a week, 2.5mg, 5mg or 10mg SHR4640 once daily for 4 weeks

DRUG

benzbromarone

25mg benzbromarone once daily for a week, 50mg benzbromarone once daily for 4 weeks

Trial Locations (1)

200127

Jiangsu Hengrui Medicine Co., Ltd., Shanghai

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT03185793 - Dose-finding and Safety Study of SHR4640 in Subjects With Hyperuricemia | Biotech Hunter | Biotech Hunter